Benign Prostatic Hyperplasia Prevention: Scoping Review with ☸️SAIMSARA.

Name: SAIMSARA Evidence Object longevity::PROSTATIC_HYPERPLASIA_PREVENTION_PM
Creator: SAIMSARA
License: https://saimsara.com/license/

SAIMSARA

doi:10.62487/saimsaraedc74258

SAIMSARA Journal

Machine-Readable Science • ISSN 3054-3991

Benign Prostatic Hyperplasia Prevention: Scoping Review with ☸️SAIMSARA.

Longevity & Public Health

Issue 2, Volume 1, 2026

Chat with this issue

DOI: 10.62487/saimsaraedc74258

Editorial note

• Last update: 2026-06-07 11:04:17

What is this paper about

Benign prostatic hyperplasia may be driven as much by metabolic dysfunction, inflammation, frailty, and lifestyle as by the prostate itself. This review maps the strongest human and experimental evidence—from HDL and fatty liver disease to immune markers, microbiome pathways, and emerging preventive targets—making the full read valuable for anyone seeking the complete prevention landscape.

Human-verified editorial review Verified by World ID proof-of-human. This editorial layer was submitted from a SAIMSARA account verified as a unique human.

saimsara.com

Abstract: This scoping review aims to systematically map and synthesize the current evidence from experimental and clinical studies on the prevention of benign prostatic hyperplasia (BPH), identifying key modifiable risk factors, protective pathways, and emerging therapeutic targets. The review uses 46 references and builds its evidence map from 24 original studies with 294063 total participants/sample observations (topic-deduplicated ΣN). The evidence mapped in this review indicates that BPH prevention is most coherently framed as the management of systemic metabolic and inflammatory health, rather than a prostate-isolated process. Recurrent signals support a protective role for favorable lipid profiles, with HDL cholesterol associated with a 17% lower risk (HR=0.83), and an elevated risk linked to metabolic dysfunction, inflammation, and frailty trajectories, where high-increasing frailty conferred nearly 3-fold higher risk (OR 2.82). Preclinical work on antioxidant and anti-inflammatory compounds further highlights converging mechanisms, though human preventive efficacy remains unproven. Clinically, this suggests integrating metabolic, inflammatory, and lifestyle assessment into BPH risk stratification for aging men. Future randomized trials should test whether targeted modulation of metabolic-inflammatory pathways translates into measurable reductions in BPH incidence and progression.
.

Keywords: prostatic hyperplasia prevention; benign prostatic hyperplasia; metabolic syndrome; inflammation; oxidative stress; gut microbiota; lipid metabolism; frailty; lifestyle modification; dietary calcium

Review Stats

Final search date and database lock: 2026-05-29 14:42:39 CEST
Plan: Pro (expanded craft tokens; source: PubMed)
Source: PubMed
Total Abstracts/Papers: 446
Downloaded Abstracts/Papers: 75
Included original and non-original Abstracts/Papers (all): 62
Included original Abstracts/Papers (Vote counting by direction of effect): 24
Reference Index (links used in paper): 46
Total participants/sample observations (topic deduplicated ΣN): 294063

Get access to the full paper

Unlock the full evidence map

Full paper access includes the complete human-readable review, figures, reference index, PDF export, and machine-readable Evidence JSON download.
Evidence JSON can also be purchased separately if you only need the LLM-ready object for agent, AI, or RAG workflows.
Institutional or library access? Sign in with your institution email to open all available SAIMSARA papers under your institution access arrangement.
Need a SAIMSARA review on your own topic? ☸️Request.

Reference Index (46)

[1] Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. — https://doi.org/10.4081/aiua.2019.3.139
[2] Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021. — https://doi.org/10.1186/s40779-024-00569-w
[3] Drug-induced urinary retention: incidence, management and prevention. — https://doi.org/10.2165/00002018-200831050-00002
[4] Targeting benign prostate hyperplasia treatments: AR/TGF-β/NOX4 inhibition by apocynin suppresses inflammation and proliferation. — https://doi.org/10.1016/j.jare.2023.04.006
[5] Prevention of benign prostatic hyperplasia disease. — https://doi.org/10.1016/j.juro.2006.06.022
[6] Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm. — https://doi.org/10.5534/wjmh.200012
[7] Salmonella enterica mediated epigenetic promotion of fibrosis is a novel factor in benign prostatic hyperplasia. — https://doi.org/10.1186/s40779-025-00614-2
[8] The prevention of benign prostatic hyperplasia (bph). — https://doi.org/10.1016/j.mehy.2016.12.013

Unlock the full paper to view the complete Reference Index.